
|Videos|January 25, 2019
Data Suggest Potential for Immunotherapy in HCC
Author(s)Raymond Wadlow, MD
Raymond Wadlow, MD, discusses interesting data presented for hepatocellular carcinoma at the 2018 Gastrointestinal Cancers Symposium.
Advertisement
Raymond Wadlow, MD, a medical oncologist at Virginia Cancer Specialists, discusses interesting data presented for hepatocellular carcinoma (HCC) at the 2018 Gastrointestinal Cancers Symposium.
One analysis looked at the role of neoadjuvant immunotherapy in patients with resectable HCC. While this is a small subset of patients, Wadlow says that 3 of the 8 patients had pathologic complete responses, 2 with a checkpoint combination and 1 with a single-agent PD-L1 inhibitor.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
Gemogenovatucel-T Triples Overall Survival in High-Risk HRP Ovarian Cancer
3
Building Better ADCs for GI Cancers: Targets, Timing, and Toxicities
4
CD47 Expression Serves as Predictive Biomarker for HER2+ Breast Cancer
5



















